Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $4.8052W HIGH $8.95
Volume
250.74 K
Value Traded
401.53 K
Short % Float
4.44%
+19.86%Week
+2.94%1 Month
-0.57%3 Month
+17.65%6 Month
-64.01%5 Year
-32.94%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
250.98 M
EPS (TTM)
-0.90
P/E Ratio
-
Ent. Value
227.20 M
Total Shares
36.53 M
Float Shares
35.42 M
Insiders
3.05%
Institutions
45.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PROF Catalyst Timeline
Dated clinical, regulatory and corporate events for Profound Medical Corp.
Past FDA Catalysts and PDUFA Decisions
How PROF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Profound Medical Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PROF program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TULSA Procedure | localized prostate cancer | 2026-03-13 | preservation of function: both function 50%, continence 84%, erectile function 56%; robotic rp results: both function 24%, continence 49%, erectile function 47%; perioperative measures: blood loss 0 mL, hospital stay 0.3 days, days off work 10 daysRead More | CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary ContinenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Menawat Arun SwarupDirector, Officer (CEO) | Buy | 12,027 587,089 held | $4.73 | 05/16/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in PROF
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| DAFNA Capital Management LLC | 0.3 % (-25 %) | 1.73 M | 260.36 K | -1.01% ( -2.65 K) |
PROF Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PROF ranks across every disease it competes in
Competitive Position is a premium feature
See how PROF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPROF News
PROF▲ +21.7%on this news
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Profound Medical Corp. has reported preliminary unaudited revenues for Q3 2026, anticipating record-breaking figures between $9.8 million and $10.0 million. This represents a significant year-over-year growth of approximately 85% to 89% compared to Q3 2025. The company also expects a gross margin exceeding 70%, highlighting strong commercial momentum and increased customer adoption.
Read more →PROFProfound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference
Profound Medical Corp. will participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth Conference on September 10, 2026. The event will feature one-on-one investor meetings, although no webcast will be available. Profound is known for its innovative interventional MRI procedures, including TULSA-PRO and Sonalleve, which provide incision-free treatment options for various medical conditions.
Read more →PROFProfound Medical Announces Management Change
Profound Medical Corp. has announced the promotion of Matthew Sobczyk to Interim Chief Financial Officer, succeeding Rashed Dewan. Sobczyk, who joined the company in 2020, is expected to maintain operational discipline and support the company's growth strategy. The CEO expressed gratitude for Dewan's contributions during his tenure.
Read more →PROFProfound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
Profound Medical Corp. has launched 'Let's Huddle', a global community aimed at supporting men through their prostate care journey. Led by prostate cancer survivor Leonard Wheeler, this initiative focuses on education, peer support, and advocacy. It aims to empower patients and their families, ensuring they are informed and connected throughout their treatment process.
Read more →PROF▼ -6.7%on this news
Profound Medical Reports Second Quarter 2026 Financial Results
Profound Medical Corp. reported a 39% improvement in net loss for Q2 2026, driven by a 16% decline in operating expenses. The company achieved record new purchase orders exceeding $7 million, although $3.1 million in revenue recognition shifted to Q3 due to shipping delays. Profound continues to expand payer coverage for its TULSA Procedure, enhancing patient access. The company maintains its revenue guidance of $25 million for the year.
Read more →PROFProfound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
Profound Medical Corp. will release its second quarter 2026 financial results on August 6, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and business developments. The company specializes in innovative interventional MRI procedures, including the TULSA-PRO and Sonalleve technologies, which are approved in various global markets.
Read more →PROFProfound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
Profound Medical Corp. will showcase its MRI-guided, AI-powered TULSA Procedure at the Society of Robotic Surgery Annual Meeting in Fort Lauderdale from July 23-26, 2026. Leading physicians will present various studies demonstrating the efficacy and safety of the TULSA Procedure for prostate cancer treatment. The company is also participating in an investor session to discuss its innovative technologies.
Read more →PROFProfound to Showcase TULSA-PRO , the TULSA Procedure™ and the Future of iMRI at AUA2026
Profound Medical Corp. is set to showcase the TULSA Procedure™ at the upcoming AUA2026 annual meeting, with several presentations planned by noted physicians. The company will demonstrate the TULSA-PRO® system and highlight the potential integration of PSMA PET imaging to improve treatment planning for prostate cancer. Experts will discuss the effectiveness of the procedure in addressing localized prostate cancer and the benefits of personalized treatment. This emphasis on innovative imaging and treatment strategies positions Profound as a leader in the emerging field of MRI-guided therapies.
Read more →PROFProfound Medical Reports Strong First Quarter 2026 Financial Results
Profound Medical Corp. reported impressive financial results for Q1 2026, showcasing a 104% increase in revenue year-over-year. The company's TULSA Procedure has gained coverage from Humana, enhancing access for many patients. Profound anticipates the full-year 2026 revenue to reach around $25 million, marking a 56% increase from the previous year. Despite these positives, the company still faces challenges in accurately predicting short-term revenues and recorded a net loss of approximately $7 million for the quarter.
Read more →PROFProfound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow
Profound Medical Corp. will announce its first quarter 2026 financial results on May 7, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and business developments. Profound specializes in AI-powered, MRI-guided therapies for tissue ablation, enhancing patient outcomes and procedural control.
Read more →PROFProfound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Profound Medical Corp. will present an update on its business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on April 22, 2026. The presentation will highlight the company's advancements in AI-powered, MRI-guided therapies for treating various prostate conditions and other medical applications. Profound's technologies aim to improve clinical outcomes while minimizing side effects associated with traditional surgical methods.
Read more →PROFProfound Medical Corp. Investigated by the Portnoy Law Firm
Profound Medical Corp. is currently under investigation by the Portnoy Law Firm for potential securities fraud. The inquiry comes after the company admitted to an error that overstated its revenue by $472,000 in Q1 2024. As a result of this disclosure, the company's stock price dropped by 5.9%, leading to concerns among investors. The firm is offering complimentary case evaluations to affected investors as they consider pursuing class-action claims.
Read more →PROFIncision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Profound Medical Corp. will showcase its TULSA-PRO system at the 2026 Society of Interventional Radiology Annual Scientific Meeting. The TULSA Procedure, which utilizes MRI-guided, incision-free technology, aims to treat prostate cancer and benign prostatic hyperplasia effectively. Presentations will highlight its clinical outcomes and innovative approaches to prostate care.
Read more →PROFProfound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
Profound Medical Corp. announced that Texas Prostate has successfully completed its 100th TULSA Procedure at the Dallas Medical Center. This innovative procedure utilizes MRI guidance to treat various prostate conditions with improved safety and precision. Following a shift to a Medicare model, the number of procedures performed has surged by 500%, indicating strong demand and adoption among urologists in the region.
Read more →PROFCAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
The CAPTAIN trial demonstrated that the TULSA Procedure significantly outperforms robotic radical prostatectomy in preserving erectile function and urinary continence at six months post-treatment. With a successful enrollment of 211 patients, the trial met its primary safety endpoint, showing a marked improvement in quality of life outcomes. The results suggest that TULSA could become a standard treatment for localized prostate cancer.
Read more →PROFProfound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Profound Medical Corp. will present the first clinical outcomes from the CAPTAIN trial at the EAU 2026 Congress on March 13, 2026. The trial compares the TULSA Procedure with robotic radical prostatectomy for localized prostate cancer. Following the presentation, an investor webinar will discuss the clinical data and its implications for prostate cancer treatment guidelines. Additionally, Profound will participate in the ROTH Conference from March 22-24, 2026.
Read more →PROFProfound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Profound Medical Corp. reported strong financial results for Q4 and the full year of 2025, achieving record revenues driven by a growing TULSA-PRO sales pipeline. The company anticipates increasing its installed base to about 120 by the end of 2026. Despite these successes, Profound experienced a net loss of $8.2 million for Q4 2025, reflecting rising operating expenses and decreased gross margins. Looking ahead, upcoming clinical trial results may influence future growth and profitability.
Read more →PROFProfound Medical Honored with INOVAIT’s 2025–2026 Mount Logan Award Recognizing the TULSA Procedure™ for Prostate Disease
Profound Medical Corp. has been awarded the 2025/2026 Mount Logan Award by INOVAIT for its innovative TULSA Procedure, which has treated over 4,000 patients. The award recognizes the company's achievements in interventional MRI and its efforts to expand patient access globally. The TULSA Procedure offers a precise and minimally invasive treatment for prostate conditions, enhancing patient recovery and reducing side effects.
Read more →PROFProfound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow
Profound Medical Corp. (NASDAQ: PROF) will announce its fourth quarter and full year 2025 financial results after market close on March 5, 2026. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss the results and relevant business developments. The company specializes in interventional MRI procedures, specifically the TULSA-PRO system, which shows promise for treating various prostate-related conditions.
Read more →PROF▼ -7.3%on this news
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
Profound Medical Corp. announced that PRO FAMILIA Specialist Hospital in Poland has completed its 500th Sonalleve procedure, providing women with a non-invasive treatment for gynecologic conditions. The MRI-guided therapy offers targeted relief without incisions, reducing complications and preserving fertility. The technology is gaining traction internationally, with over 4,000 women treated so far.
Read more →About Profound Medical Corp.
Headquarters2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, A6, L4W 5K5
BIOPHARMAWATCH ELITE PLUS
Trade the next PROF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime